Health News

OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced that we have completed the transfer of all rights for RADICAVA (edaravone), including intellectual property rights and sales rights, in major countries and regions to our company from Tanabe Pharma Corporation. Transfer of rights in additional countries and regions is forthcoming. The acquisition and integration of RADICAVA team memb...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage company dedicated to developing targeted therapies to treat patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG). Fore Bio believes this is the first BTD granted to a targeted therapy for HGG. Plixorafenib is a novel BRAF inhibitor that is...

DEERFIELD BEACH, Fla.--(BUSINESS WIRE)--Premier Radiology Services (Premier) is excited to announce the acquisition of Global Imaging Solutions (GLOBIS), a leading teleradiology group providing subspecialty imaging interpretations to outpatient imaging centers and orthopedic practices. The addition of GLOBIS further expands Premier’s subspecialized capabilities and strengthens its ability to support advanced diagnostic imaging needs nationwide. “Welcoming the GLOBIS team marks another exciting...

NEW YORK--(BUSINESS WIRE)--As part of its efforts to offer and drive utilization of high-impact, family-friendly benefits for employers of all sizes, The Guardian Life Insurance Company of America® (Guardian) announced the completed integration of FINEOS AdminSuite for Employee Benefits into Guardian Absence Solutions™. Whether a boutique business or booming enterprise, Guardian’s absence management solutions provide an integrated experience that supports all aspects of leave planning, from pre...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization. ALTO-101 did not achieve statistical significance on primary e...

DENVER--(BUSINESS WIRE)--Principal Real Estate Income Fund (the “Fund”), which is traded on the New York Stock Exchange under the symbol “PGZ,” announced the declaration of monthly distributions of $0.105 per common share, payable on the dates noted below. Based on the Fund’s current net asset value share price of $10.98 (as of market close on March 26, 2026), the distributions represent an annualized distribution rate of 11.48%. The following dates apply to the distributions declared: Ex Date...

VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,589,099 on March 31, 2026. The patent, titled “ALPHA-1062 for treating Traumatic Brain Injury,” includes claims covering methods of treating...

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin...

TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company that designs, manufactures, and sells the Invisalign® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that it will report first quarter 2026 financial results on Wednesday, April 29, 2026, after the close of market. Financial results will be released at 4:00 p.m. ET (1:00 p.m. PT) and w...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subjec...